Bristol-myers Squibb Compnay

Qihong Zhao

Mohan Srinivasan

Guodong Chen

Ginger Chao Rakestraw

Richard Y Huang

Shrikant Deshpande

Steven Sheriff

John P Throup

Huadong Sun

Cristian Rodriguez

Rose A Dibella

Percy H Carter

Peggy Ann Scherle

Kimberly A Solomon

Joseph E Dinchuk

Paul Davies

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

IP-10 antibodies and their uses

The present invention relates to a chimeric chemokine receptor comprising two components: a first sequence comprising the N terminus through the last residue of the seven helix TM region of a first chemokine receptor joined with a second sequence comprising the C terminus of a second chemokine receptor extending from the first intracellular residue of the chemokine receptor to the last residue of the chemokine receptor. The chimeric chemokine receptor can be employed in various applications, such as ligand binding and screening assays and signalling assays. The chimeric chemokine receptor can also form a component of a chemokine receptor modulator design program.

Polynucleotides encoding chimeric chemokine receptors

Growing community of inventors

Princeton, NJ, United States of America

Qihong Zhao